Janice Jang1, Benjamin Kwok2, Hua Zhong3, Yuhe Xia3, Alexis Grucela4, Mitchell Bernstein4, Feza Remzi4, David Hudesman1, Jingjing Chen5, Jordan Axelrad1, Shannon Chang6. 1. Division of Gastroenterology and Hepatology, New York University Langone Health, 240 East 38th Street, 23rd Floor, New York, NY, 10016, USA. 2. Department of Internal Medicine, New York University Langone Health, New York, NY, USA. 3. Department of Population Health, New York University Langone Health, New York, NY, USA. 4. Department of Surgery, New York University Langone Health, New York, NY, USA. 5. Department of Internal Medicine, Stanford University Medical Center, Stanford, CA, USA. 6. Division of Gastroenterology and Hepatology, New York University Langone Health, 240 East 38th Street, 23rd Floor, New York, NY, 10016, USA. Shannon.Chang@nyulangone.org.
Abstract
BACKGROUND: Postoperative ileus (POI) is a temporary delay of coordinated intestinal peristalsis. Alvimopan, an oral peripherally acting mu-opioid receptor antagonist approved for accelerating gastrointestinal recovery, has never been studied specifically in patients with inflammatory bowel disease (IBD). AIM: To investigate the efficacy of alvimopan in preventing POI among IBD patients. METHODS: A retrospective chart review was conducted on 246 IBD patients undergoing bowel surgery between 2012 and 2017. Data collected included demographics, IBD subtype, length of stay (LOS), postoperative gastrointestinal symptoms, and administration of alvimopan. The primary outcome was POI; secondary gastrointestinal recovery outcomes were: time to first flatus, time to first bowel movement, time to tolerating a liquid diet, time to tolerating solid food, and LOS. RESULTS: When compared with the control group, patients in the alvimopan group had shorter times to tolerating liquids and solids, first flatus, and first bowel movements (p < 0.01). LOS was shorter in the alvimopan group when compared with controls (p < 0.01). The overall incidence of POI was higher in controls than in the alvimopan group (p = 0.07). For laparoscopic surgeries, the incidence of POI was also higher in controls than in the alvimopan group (p < 0.01). On multivariable analysis, alvimopan significantly decreased time to all gastrointestinal recovery endpoints when compared to controls (p < 0.01). CONCLUSIONS: Alvimopan is effective in accelerating time to gastrointestinal recovery and reducing POI in IBD patients. While the benefits of alvimopan have been demonstrated previously, this is the first study of the efficacy of alvimopan in IBD patients.
BACKGROUND: Postoperative ileus (POI) is a temporary delay of coordinated intestinal peristalsis. Alvimopan, an oral peripherally acting mu-opioid receptor antagonist approved for accelerating gastrointestinal recovery, has never been studied specifically in patients with inflammatory bowel disease (IBD). AIM: To investigate the efficacy of alvimopan in preventing POI among IBDpatients. METHODS: A retrospective chart review was conducted on 246 IBDpatients undergoing bowel surgery between 2012 and 2017. Data collected included demographics, IBD subtype, length of stay (LOS), postoperative gastrointestinal symptoms, and administration of alvimopan. The primary outcome was POI; secondary gastrointestinal recovery outcomes were: time to first flatus, time to first bowel movement, time to tolerating a liquid diet, time to tolerating solid food, and LOS. RESULTS: When compared with the control group, patients in the alvimopan group had shorter times to tolerating liquids and solids, first flatus, and first bowel movements (p < 0.01). LOS was shorter in the alvimopan group when compared with controls (p < 0.01). The overall incidence of POI was higher in controls than in the alvimopan group (p = 0.07). For laparoscopic surgeries, the incidence of POI was also higher in controls than in the alvimopan group (p < 0.01). On multivariable analysis, alvimopan significantly decreased time to all gastrointestinal recovery endpoints when compared to controls (p < 0.01). CONCLUSIONS:Alvimopan is effective in accelerating time to gastrointestinal recovery and reducing POI in IBDpatients. While the benefits of alvimopan have been demonstrated previously, this is the first study of the efficacy of alvimopan in IBDpatients.
Authors: Justin T Brady; Eslam M G Dosokey; Benjamin P Crawshaw; Scott R Steele; Conor P Delaney Journal: Expert Rev Gastroenterol Hepatol Date: 2015-10-21 Impact factor: 3.869
Authors: Conor P Delaney; Christopher Craver; Melinda M Gibbons; Amy W Rachfal; Christine J VandePol; Suzanne F Cook; Sara A Poston; Michael Calloway; Lee Techner Journal: Ann Surg Date: 2012-04 Impact factor: 12.969
Authors: A de Buck van Overstraeten; S Van Hoef; S Vermeire; M Ferrante; S Fieuws; A Wolthuis; G Van Assche; A D'Hoore Journal: J Crohns Colitis Date: 2015-09-07 Impact factor: 9.071
Authors: Kirk Ludwig; Warren E Enker; Conor P Delaney; Bruce G Wolff; Wei Du; John G Fort; Maryann Cherubini; James Cucinotta; Lee Techner Journal: Arch Surg Date: 2008-11